TGF-β1 inhibitor disitertide and TGFβR-I inhibitor LY-364947 abrogated the MACC1-AS1 expression in GC cells, suggesting that targeting TGF-β signaling pathway may be a potential strategy to inhibit MSC-induced stemness and chemoresistance. This evidence concerns the gene MACC1 and gastric cancer.